Anaplastic large cell lymphoma, ALK-positive.

[1]  A. Ewton,et al.  Hepatosplenic T-cell lymphoma. , 2014, Blood.

[2]  S. Pileri,et al.  Anaplastic large-cell lymphoma. , 2011, Seminars in diagnostic pathology.

[3]  H. Moritake,et al.  C‐MYC rearrangement may induce an aggressive phenotype in anaplastic lymphoma kinase positive anaplastic large cell lymphoma: Identification of a novel fusion gene ALO17/C‐MYC , 2011, American journal of hematology.

[4]  R. Advani,et al.  Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma , 2010 .

[5]  P. Gaulard,et al.  Prognostic Factors and Long Term Outcome of 138 Adults with Systemic Anaplastic Large-Cell Lymphoma: a Retrospective Study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) , 2010 .

[6]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[7]  Marc Ladanyi,et al.  Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.

[8]  Enzo Medico,et al.  Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  B. Martínez-Delgado,et al.  Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets. , 2009, Critical reviews in oncology/hematology.

[10]  D. Ramies,et al.  Phase I study of an anti-CD30 Fc engineered humanized monoclonal antibody in Hodgkin lymphoma (HL) or anaplastic large cell lymphoma (ALCL) patients: Safety, pharmacokinetics (PK), immunogenicity, and efficacy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Medeiros,et al.  Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma. , 2009, Cancer research.

[12]  S. Perkins,et al.  Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: Final results of children's cancer group study 5941 , 2009, Pediatric blood & cancer.

[13]  Florian Steinberg,et al.  Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. , 2009, Neoplasia.

[14]  Gudrun Schleiermacher,et al.  Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma , 2008, Nature.

[15]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[16]  M. Ozdemirli,et al.  HIV-associated anaplastic large cell lymphoma: a report of three cases. , 2008, AIDS.

[17]  Stefano A Pileri,et al.  ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. , 2008, Blood.

[18]  Pek-Lan Khong,et al.  Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies , 2008, Annals of Hematology.

[19]  G. Inghirami,et al.  The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination , 2008, Nature Medicine.

[20]  C. Volteau,et al.  Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Briones,et al.  Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Iafrate,et al.  Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. , 2008, Cancer research.

[23]  R. Gascoyne,et al.  Genomic profiling reveals different genetic aberrations in systemic ALK‐positive and ALK‐negative anaplastic large cell lymphomas , 2008, British journal of haematology.

[24]  K. Ohtomo,et al.  FDG-PET in T-cell and NK-cell neoplasms. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[26]  S. Ansell,et al.  Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Rodríguez,et al.  New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemothe-rapy and biological therapy. , 2007, Reviews on recent clinical trials.

[28]  P. Gaulard,et al.  Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. , 2007, Blood.

[29]  V. Soumelis,et al.  From plasmacytoid to dendritic cell: Morphological and functional switches during plasmacytoid pre‐dendritic cell differentiation , 2006, European journal of immunology.

[30]  T. Barbui,et al.  Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation , 2006, Leukemia.

[31]  E. Campo,et al.  ALK-Positive Anaplastic Large Cell Lymphoma Mimicking Nodular Sclerosis Hodgkin's Lymphoma: Report of 10 Cases , 2006, The American journal of surgical pathology.

[32]  Nicola Pimpinelli,et al.  WHO-EORTC classification for cutaneous lymphomas. , 2005, Blood.

[33]  A. Rosenwald,et al.  Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-negative anaplastic large cell lymphomas. , 2005, Human pathology.

[34]  P. de Paepe,et al.  Successful treatment with allogeneic bone marrow transplantation of an early relapse of ALK-positive anaplastic large cell lymphoma. , 2005, Haematologica.

[35]  D. Weisenburger,et al.  Towards understanding the peripheral T-cell lymphomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  B. Nathwani,et al.  T-Cell Lymphoma in HIV-Infected Patients , 2004, Journal of acquired immune deficiency syndromes.

[37]  M. Boccadoro,et al.  Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[39]  Y. Shyr,et al.  Histology Impacts the Outcome of Peripheral T-Cell Lymphomas after High Dose Chemotherapy and Stem Cell Transplant , 2004, Leukemia & lymphoma.

[40]  V. Diehl,et al.  The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. , 2003, Blood.

[41]  J. Macías,et al.  Bone involvement and abcess formation by neutrophil-rich CD30+ anaplastic large-cell lymphoma mimicking skeletal infection in an AIDS patient. , 2003, The Journal of infection.

[42]  M. Crump,et al.  Autologous stem cell transplant for relapsed and refractory peripheral T‐cell lymphoma: variable outcome according to pathological subtype , 2003, British journal of haematology.

[43]  V. Diehl,et al.  The human anti-CD 30 antibody 5 F 11 shows in vitro and in vivo activity against malignant lymphoma ( Short title : Fully human anti-CD 30 antibody ) , 2003 .

[44]  V. Diehl,et al.  A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  G. Krieger,et al.  Langzeitergebnisse mit MACOP-B und Strahlentherapie bei aggressiven Non-Hodgkin-Lymphomen , 2001, Oncology Research and Treatment.

[46]  M. Kneba,et al.  [Long-term results with MACOP-B and radiation therapy for aggressive lymphomas]. , 2001, Onkologie.

[47]  S. Pileri,et al.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. , 2000, Blood.

[48]  M. Seto,et al.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype. , 2000, Blood.

[49]  E. Deconinck,et al.  Autologous stem cell transplantation for anaplastic large‐cell lymphomas: results of a prospective trial , 2000, British journal of haematology.

[50]  R. Virmani,et al.  Anaplastic large cell lymphoma (CD 30+), T-phenotype, in the heart of an HIV-positive man. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[51]  G. Delsol,et al.  Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children--a report from the French Society of Pediatric Oncology. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  E. Campo,et al.  Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. , 1999, Blood.

[53]  T. Greiner,et al.  Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. , 1999, Blood.

[54]  D. Arber,et al.  Peripheral T-cell lymphoma with Toutonlike tumor giant cells associated with HIV infection: report of two cases. , 1999, The American journal of surgical pathology.

[55]  G. Leverger,et al.  Anaplastic Large-Cell Lymphoma in Children : Analysis of 82 Patients Enrolled in Two Consecutive Studies of the French Society of Pediatric Oncology , 1998 .

[56]  S. Pileri,et al.  ALK expression defines a distinct group of T/null lymphomas ("ALK lymphomas") with a wide morphological spectrum. , 1998, The American journal of pathology.

[57]  S. Pileri,et al.  Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. , 1998, Blood.

[58]  S. Pileri,et al.  Clinical implications of serum levels of soluble CD30 in 70 adult anaplastic large-cell lymphoma patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Pileri,et al.  ALK-positive lymphoma: a single disease with a broad spectrum of morphology. , 1998, Blood.

[60]  P. Gaulard,et al.  Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. , 1997, Blood.

[61]  S. Pileri,et al.  Frequent expression of the NPM-ALK chimeric fusion protein in anaplastic large-cell lymphoma, lympho-histiocytic type. , 1997, The American journal of pathology.

[62]  E. Jaffe,et al.  Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkin's disease: evidence for distinct cellular origin. , 1997, Blood.

[63]  T. Arakawa,et al.  Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system , 1997, Oncogene.

[64]  S. Mori,et al.  Anaplastic large cell lymphomas expressing the novel chimeric protein p80NPM/ALK: a distinct clinicopathologic entity. , 1995, Leukemia.

[65]  H. Stein,et al.  Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. , 1996, Blood.

[66]  F. Gherlinzoni,et al.  Adult lymphoblastic lymphoma: clinical features and prognostic factors in 53 patients. , 1996, Leukemia & lymphoma.

[67]  A. Bernheim,et al.  High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. , 1996, Blood.

[68]  D N Shapiro,et al.  Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.

[69]  P. Brousset,et al.  Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. , 1995, American journal of clinical pathology.

[70]  G. Delsol,et al.  High incidence of Epstein–Barr virus detection in Hodgkin's disease and absence of detection in anaplastic large‐cell lymphoma in children , 1993, Histopathology.

[71]  P. Scherr,et al.  Non-Hodgkin's lymphoma and occupational exposure. , 1992, Cancer research.

[72]  A. Hagenbeek,et al.  PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  D. Weisenburger,et al.  A Case‐Control Study of Non‐Hodgkin's Lymphoma and the Herbicide 2,4‐Dichlorophenoxyacetic Acid (2, 4‐D) in Eastern Nebraska , 1990, Epidemiology.

[74]  R. Warnke,et al.  CD30‐positive large cell lymphomas (‘Ki‐1 lymphoma’) are associated with a chromosomal translocation involving 5q35 , 1990, British journal of haematology.

[75]  D. Weisenburger.  Environmental epidemiology of non-Hodgkin's lymphoma in eastern Nebraska. , 1990, American journal of industrial medicine.

[76]  C. la Vecchia,et al.  Occupation and lymphoid neoplasms. , 1989, British Journal of Cancer.

[77]  K. Lennert,et al.  The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. , 1985, Blood.

[78]  Weisenburger Dd.  Lymphoid malignancies in Nebraska: a hypothesis. , 1985 .

[79]  D. Weisenburger.  Lymphoid malignancies in Nebraska: a hypothesis. , 1985, The Nebraska medical journal.

[80]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.